Literature DB >> 25823630

Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series.

Joji Suzuki1, Jeffrey DeVido, Inder Kalra, Leena Mittal, Sejal Shah, Jennifer Zinser, Roger D Weiss.   

Abstract

BACKGROUND AND OBJECTIVES: Opioid dependent patients are hospitalized frequently. We aimed to determine if initiation of buprenorphine treatment during hospitalization facilitates entry into treatment following discharge.
METHODS: Retrospective case series (n = 47).
RESULTS: Twenty-two (46.8%) patients successfully initiated buprenorphine treatment within 2 months of discharge. Those patients obtaining a referral to a specific program were more successful in continuing treatment, but this difference did not reach statistical significance (59.1% vs 39.1%, p = 0.18). DISCUSSION AND
CONCLUSIONS: Hospitalization may be an important opportunity to engage opioid dependent patients to initiate buprenorphine treatment. SCIENTIFIC SIGNIFICANCE: This study provides provisional support for utilizing buprenorphine for hospitalized patients. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25823630     DOI: 10.1111/ajad.12161

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  17 in total

1.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

2.  Opioid-related US hospital discharges by type, 1993-2016.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2019-05-10

3.  Capsule Commentary on Velez et al., "It's Been an Experience, a Life Learning Experience": A Qualitative Study of Hospitalized Patients with Substance Use Disorders.

Authors:  Maria G Frank
Journal:  J Gen Intern Med       Date:  2017-03       Impact factor: 5.128

Review 4.  Caring for patients with opioid use disorder in the hospital.

Authors:  Joseph H Donroe; Stephen R Holt; Jeanette M Tetrault
Journal:  CMAJ       Date:  2016-09-19       Impact factor: 8.262

5.  U.S. National 90-Day Readmissions After Opioid Overdose Discharge.

Authors:  Cora Peterson; Yang Liu; Likang Xu; Nisha Nataraj; Kun Zhang; Christina A Mikosz
Journal:  Am J Prev Med       Date:  2019-04-17       Impact factor: 5.043

6.  Peer providers and linkage with buprenorphine care after hospitalization: A retrospective cohort study.

Authors:  Helen E Jack; Eric D Denisiuk; Brett A Collins; Dan Stephens; Kendra L Blalock; Jared W Klein; Elenore P Bhatraju; Joseph O Merrill; Kevin A Hallgren; Judith I Tsui
Journal:  Subst Abus       Date:  2022-12       Impact factor: 3.984

7.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

8.  Injection Drug Use-Associated Candidemia: Incidence, Clinical Features, and Outcomes, East Tennessee, 2014-2018.

Authors:  John A Rossow; Radhika Gharpure; Julia Brennan; Pryanka Relan; Sabrina R Williams; Snigdha Vallabhaneni; Brendan R Jackson; Caroline R Graber; Sherry R Hillis; William Schaffner; John R Dunn; Timothy F Jones
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

9.  Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting.

Authors:  Joji Suzuki
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

10.  Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment.

Authors:  Nicholaus Christian; Richard Bottner; Amber Baysinger; Alanna Boulton; Blair Walker; Victoria Valencia; Christopher Moriates
Journal:  J Hosp Med       Date:  2021-06       Impact factor: 2.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.